Cellectis S.A. ALCLS.PA Stock
Cellectis S.A. Price Chart
Cellectis S.A. ALCLS.PA Financial and Trading Overview
| Cellectis S.A. stock price | 2.52 EUR |
| Previous Close | 2.62 EUR |
| Open | 2.63 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 2.6 - 2.64 EUR |
| 52 Week Range | 0.89 - 3.9 EUR |
| Volume | 15.81K EUR |
| Avg. Volume | 379.4K EUR |
| Market Cap | 189.41M EUR |
| Beta (5Y Monthly) | 3.134 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.31 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.33 EUR |
ALCLS.PA Valuation Measures
| Enterprise Value | 161.69M EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.3132744 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.7230196 |
| Price/Book (mrq) | 1.9080292 |
| Enterprise Value/Revenue | 6.593 |
| Enterprise Value/EBITDA | -2.5 |
Trading Information
Cellectis S.A. Stock Price History
| Beta (5Y Monthly) | 3.134 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 3.9 EUR |
| 52 Week Low | 0.89 EUR |
| 50-Day Moving Average | 1.98 EUR |
| 200-Day Moving Average | 1.87 EUR |
ALCLS.PA Share Statistics
| Avg. Volume (3 month) | 379.4K EUR |
| Avg. Daily Volume (10-Days) | 193.19K EUR |
| Shares Outstanding | 71.58M |
| Float | 32.33M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 15.45% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1257.29% |
| Gross Margin | 94.85% |
| EBITDA Margin | -263.74% |
Management Effectiveness
| Return on Assets (ttm) | -18.77% |
| Return on Equity (ttm) | -71.27% |
Income Statement
| Revenue (ttm) | 24.53M EUR |
| Revenue Per Share (ttm) | 0.47 EUR |
| Quarterly Revenue Growth (yoy) | -12.50% |
| Gross Profit (ttm) | 23.95M EUR |
| EBITDA | -64684000 EUR |
| Net Income Avi to Common (ttm) | -71889000 EUR |
| Diluted EPS (ttm) | -1.31 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 67.36M EUR |
| Total Cash Per Share (mrq) | 1.21 EUR |
| Total Debt (mrq) | 83.53M EUR |
| Total Debt/Equity (mrq) | 109.73 EUR |
| Current Ratio (mrq) | 2.195 |
| Book Value Per Share (mrq) | 1.37 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -52871000 EUR |
| Levered Free Cash Flow (ttm) | -47694752 EUR |
Profile of Cellectis S.A.
| Country | France |
| State | N/A |
| City | Paris |
| Address | 8, rue de la Croix Jarry |
| ZIP | 75013 |
| Phone | 33 1 81 69 16 00 |
| Website | https://www.cellectis.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 231 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Q&A For Cellectis S.A. Stock
What is a current ALCLS.PA stock price?
Cellectis S.A. ALCLS.PA stock price today per share is 2.52 EUR.
How to purchase Cellectis S.A. stock?
You can buy ALCLS.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cellectis S.A.?
The stock symbol or ticker of Cellectis S.A. is ALCLS.PA.
Which industry does the Cellectis S.A. company belong to?
The Cellectis S.A. industry is Biotechnology.
How many shares does Cellectis S.A. have in circulation?
The max supply of Cellectis S.A. shares is 71.95M.
What is Cellectis S.A. Price to Earnings Ratio (PE Ratio)?
Cellectis S.A. PE Ratio is now.
What was Cellectis S.A. earnings per share over the trailing 12 months (TTM)?
Cellectis S.A. EPS is -1.31 EUR over the trailing 12 months.
Which sector does the Cellectis S.A. company belong to?
The Cellectis S.A. sector is Healthcare.